Gastric Cancer Patients Receiving Maintenance Hemodialysis After Surgery With and Without Postoperative Chemotherapy: A Case Series of 6

Abstract

Background: The management of gastric cancer patients who received gastrectomy and/or postoperative chemotherapy is of high importance. However, the safety and efficacy of chemotherapy in hemodialysis patients have not been established. In this study, we report 6 cases of hemodialysis patients who underwent gastrectomy for gastric cancer. Case Presentation: The presented cases included 5 men and 1 woman, with a mean age of 66.3 years (range, 59-74 years). All patients underwent standard laparotomy, with 3 of 6 patients (50%) experiencing postoperative complications. Three patients who did not experience any postoperative complications could receive subsequent chemotherapy. S-1 chemotherapy regimen and uracil and tegafur chemotherapy regimen were administered to 1 and 2 patients, respectively. These 3 patients did not experience any chemotherapyrelated side effects. Among the 4 patients who received a diagnosis of pathologic stages II to III, 2 patients treated with postoperative chemotherapy achieved better prognoses than those who did not receive chemotherapy (mean, 25.5 versus 5.0 months). Discussion and Conclusion: Hemodialysis patients with gastric cancer who received gastrectomy exhibited a high morbidity rate. Postoperative chemotherapy can be performed immediately after surgery in patients who do not experience postoperative complications. S-1 regimen and uracil and tegafur regimen could be administered safely in hemodialysis patients. Postoperative chemotherapy may lead to a good prognosis in gastric cancer patients receiving hemodialysis.